

Anthony C Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2595452/publications.pdf>

Version: 2024-02-01

140
papers

18,962
citations

36271

51
h-index

14197

128
g-index

165
all docs

165
docs citations

165
times ranked

21899
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e224-e233.	2.9	10
2	A Novel Role for Cytochrome P450 Epoxygenase Metabolites in Septic Shock. , 2022, 4, e0622.		3
3	Namulumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 255-266.	5.2	32
4	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	13.7	174
5	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0228321.	1.8	5
6	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	3.8	83
7	Stimulation of Neutrophils in Whole Blood Enhances the Pro-inflammatory Activity of Neutrophil-Derived Microvesicles. <i>FASEB Journal</i> , 2022, 36, .	0.2	1
8	Redefining critical illness. <i>Nature Medicine</i> , 2022, 28, 1141-1148.	15.2	136
9	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0270668.	1.1	16
10	Vasopressor Therapy in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 059-077.	0.8	30
11	Levels of Autonomy and Safety Assurance for AI-Based Clinical Decision Systems. <i>Lecture Notes in Computer Science</i> , 2021, , 291-296.	1.0	3
12	Current use of inotropes in circulatory shock. <i>Annals of Intensive Care</i> , 2021, 11, 21.	2.2	35
13	Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L Study protocol for a randomised trial. <i>BMJ Open</i> , 2021, 11, e043194.	0.8	3
14	Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-90.	1.3	4
15	Sepsis Subclasses: A Framework for Development and Interpretation*. <i>Critical Care Medicine</i> , 2021, 49, 748-759.	0.4	81
16	Emerging Lessons From COVID-19 for the US Clinical Research Enterprise. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1159.	3.8	43
17	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 1491-1502.	13.9	1,419
18	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194

#	ARTICLE	IF	CITATIONS
19	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
20	Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom. <i>Intensive Care Medicine</i> , 2021, 47, 549-565.	3.9	49
21	Protocol summary and statistical analysis plan for the Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (SuDDICU) crossover, cluster randomised controlled trial. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2021, 23, 183-193.	0.0	2
22	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Medicine</i> , 2021, 47, 867-886.	3.9	65
23	The future of acute and emergency care. <i>Future Healthcare Journal</i> , 2021, 8, e230-e236.	0.6	1
24	Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-104.	0.9	11
25	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	13.9	778
26	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
27	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	13.9	712
28	Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1013.	3.8	108
29	Effect of Convalescent Plasma on Organ Support—Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	3.8	169
30	A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 891-901.	2.5	38
31	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
32	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and health economic analysis plan for the 65 trial in article. <i>Journal of the Intensive Care Society</i> , 2020, 21, 230-231.	1.1	2
33	Effects of low-dose hydrocortisone and hydrocortisone plus fludrocortisone in adults with septic shock: a protocol for a systematic review and meta-analysis of individual participant data. <i>BMJ Open</i> , 2020, 10, e040931.	0.8	3
34	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 691.	0.7	62
35	Validating a prediction tool to determine the risk of nosocomial multidrug-resistant Gram-negative bacilli infection in critically ill patients: A retrospective case-control study. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 826-831.	0.9	2
36	A minimal common outcome measure set for COVID-19 clinical research. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e192-e197.	4.6	1,165

#	ARTICLE	IF	CITATIONS
37	Subphenotypes in critical care: translation into clinical practice. <i>Lancet Respiratory Medicine</i> , 2020, 8, 631-643.	5.2	117
38	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1317.	3.8	671
39	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1330.	3.8	1,855
40	Corticosteroid therapy for critically ill patients with COVID-19: A structured summary of a study protocol for a prospective meta-analysis of randomized trials. <i>Trials</i> , 2020, 21, 734.	0.7	30
41	Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1209-1218.	5.2	174
42	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Protocol for the 65 randomised clinical trial. <i>Journal of the Intensive Care Society</i> , 2020, 21, 281-282.	1.1	1
43	Global outbreak research: harmony not hegemony. <i>Lancet Infectious Diseases</i> , 2020, 20, 770-772.	4.6	40
44	Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. <i>BMJ</i> , 2020, 368, m689.	3.0	509
45	Methylaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial. <i>Intensive Care Medicine</i> , 2020, 46, 747-755.	3.9	18
46	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Trial. <i>Intensive Care Medicine</i> , 2020, 45, 1049-1051.	9.5	245
47	Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 938.	3.8	169
48	Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. <i>Intensive Care Medicine</i> , 2019, 45, 1392-1400.	3.9	33
49	Early May Be Better: Early Low-Dose Norepinephrine in Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1049-1051.	2.5	12
50	Methodological challenges in European ethics approvals for a genetic epidemiology study in critically ill patients: the GenOSept experience. <i>BMC Medical Ethics</i> , 2019, 20, 30.	1.0	11
51	Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. <i>Critical Care</i> , 2019, 23, 156.	2.5	27
52	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. <i>Intensive Care Medicine</i> , 2019, 45, 844-855.	3.9	97
53	Effectiveness of a national quality improvement programme to improve survival after emergency abdominal surgery (EPOCH): a stepped-wedge cluster-randomised trial. <i>Lancet</i> , 2019, 393, 2213-2221.	6.3	123
54	Current use of vasopressors in septic shock. <i>Annals of Intensive Care</i> , 2019, 9, 20.	2.2	109

#	ARTICLE	IF	CITATIONS
55	Lessons from the ICU: Choosing the Right Vasopressor. Lessons From the ICU, 2019, , 367-377.	0.1	0
56	Why Understanding Sepsis Endotypes Is Important for Steroid Trials in Septic Shock. Critical Care Medicine, 2019, 47, 1782-1784.	0.4	12
57	Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial*. Critical Care Medicine, 2019, 47, 1743-1750.	0.4	26
58	Supervised machine learning for the prediction of infection on admission to hospital: a prospective observational cohort study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1108-1115.	1.3	26
59	Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 980-986.	2.5	178
60	Real time self-rating of decision certainty by clinicians: a systematic review. Clinical Medicine, 2019, 19, 369-374.	0.8	6
61	Immune therapy in sepsis: Are we ready to try again?. Journal of the Intensive Care Society, 2018, 19, 326-344.	1.1	49
62	Delivering precision antimicrobial therapy through closed-loop control systems. Journal of Antimicrobial Chemotherapy, 2018, 73, 835-843.	1.3	28
63	Innovation and safety in critical care: should we collaborate with the industry? Pro. Intensive Care Medicine, 2018, 44, 2276-2278.	3.9	1
64	Evidence for a protective role for the rs805305 single nucleotide polymorphism of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in septic shock through the regulation of DDAH activity. Critical Care, 2018, 22, 336.	2.5	17
65	Profiling inflammatory markers in patients with pneumonia on intensive care. Scientific Reports, 2018, 8, 14736.	1.6	12
66	Are large randomised controlled trials in severe sepsis and septic shock statistically disadvantaged by repeated inadvertent underestimates of required sample size?. BMJ Open, 2018, 8, e020068.	0.8	12
67	The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nature Medicine, 2018, 24, 1716-1720.	15.2	629
68	Terlipressin or norepinephrine, or both in septic shock?. Intensive Care Medicine, 2018, 44, 1964-1966.	3.9	10
69	Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis. Annals of Intensive Care, 2018, 8, 16.	2.2	2
70	Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock. JAMA - Journal of the American Medical Association, 2018, 319, 1889.	3.8	145
71	A global perspective on vasoactive agents in shock. Intensive Care Medicine, 2018, 44, 833-846.	3.9	69
72	Sepsis: who will shoot first? Pharma or diagnostics?. Intensive Care Medicine, 2018, 44, 1331-1333.	3.9	3

#	ARTICLE	IF	CITATIONS
73	Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Efficacy and Mechanism Evaluation, 2018, 5, 1-94.	0.9	3
74	Levosimendan in Sepsis. New England Journal of Medicine, 2017, 376, 798-800.	13.9	10
75	The intensive care medicine research agenda on septic shock. Intensive Care Medicine, 2017, 43, 1294-1305.	3.9	61
76	Metabolic Profiling in Patients with Pneumonia on Intensive Care. EBioMedicine, 2017, 18, 244-253.	2.7	19
77	Statin therapy for acute respiratory distress syndrome: an individual patient data meta-analysis of randomised clinical trials. Intensive Care Medicine, 2017, 43, 663-671.	3.9	33
78	Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 328-339.	2.5	178
79	Derivation and validation of a prognostic model for postoperative risk stratification of critically ill patients with faecal peritonitis. Annals of Intensive Care, 2017, 7, 96.	2.2	7
80	Current practice in the management of new-onset atrial fibrillation in critically ill patients: a UK-wide survey. PeerJ, 2017, 5, e3716.	0.9	29
81	Protocol for a randomised control trial of methylalantrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION). BMJ Open, 2016, 6, e011750.	0.8	6
82	Multicountry survey of emergency and critical care medicine physicians' fluid resuscitation practices for adult patients with early septic shock. BMJ Open, 2016, 6, e010041.	0.8	15
83	Who Says There Is No "I'm in Team"? Achieving Individual Success in Collaborative Clinical Research in Critical Care. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 911-912.	2.5	0
84	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Medicine, 2016, 42, 1958-1969.	3.9	151
85	Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. New England Journal of Medicine, 2016, 375, 1638-1648.	13.9	271
86	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2016, 316, 509.	3.8	456
87	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. International Journal of Cardiology, 2016, 222, 303-312.	0.8	103
88	Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-analysis. Journal of the Intensive Care Society, 2016, 17, 136-145.	1.1	13
89	Metabonomics and intensive care. Critical Care, 2016, 20, 68.	2.5	15
90	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respiratory Medicine, 2016, 4, 259-271.	5.2	536

#	ARTICLE	IF	CITATIONS
91	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	1.3	129
92	Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review. <i>Health Technology Assessment</i> , 2016, 20, 1-118.	1.3	62
93	Monocyte Tumor Necrosis Factor- α "Converting Enzyme Catalytic Activity and Substrate Shedding in Sepsis and Noninfectious Systemic Inflammation". <i>Critical Care Medicine</i> , 2015, 43, 1375-1385.	0.4	5
94	Variants in the Mannose-binding Lectin Gene <i>MBL2</i> do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. <i>Clinical Infectious Diseases</i> , 2015, 61, 695-703.	2.9	24
95	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2015, 3, 53-60.	5.2	166
96	Evidence about inotropes: when is enough, enough?. <i>Intensive Care Medicine</i> , 2015, 41, 695-697.	3.9	0
97	Differentiating sepsis from non-infectious systemic inflammation based on microvesicle-bacteria aggregation. <i>Nanoscale</i> , 2015, 7, 13511-13520.	2.8	29
98	What's new in vasopressin?. <i>Intensive Care Medicine</i> , 2015, 41, 2177-2179.	3.9	11
99	Association between trends in clinical variables and outcome in intensive care patients with faecal peritonitis: analysis of the GenOSept cohort. <i>Critical Care</i> , 2015, 19, 210.	2.5	10
100	Thoracic Epidural analgesia versus Rectus Sheath Catheters for open midline incisions in major abdominal surgery within an enhanced recovery programme (TERSC): study protocol for a randomised controlled trial. <i>Trials</i> , 2014, 15, 400.	0.7	27
101	Protocol for a randomised controlled trial of Vasopressin versus Noradrenaline as Initial therapy in Septic shock (VANISH). <i>BMJ Open</i> , 2014, 4, e005866-e005866.	0.8	24
102	The Interaction of Vasopressin and Corticosteroids in Septic Shock. <i>Critical Care Medicine</i> , 2014, 42, 1325-1333.	0.4	106
103	Open source clinical science for emerging infections. <i>Lancet Infectious Diseases</i> , 2014, 14, 8-9.	4.6	82
104	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	2.9	843
105	Comment on: Effects of selective digestive decontamination (SDD) on the gut resistome. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3444-3445.	1.3	3
106	An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 199.	0.7	36
107	Patients with faecal peritonitis admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. <i>Intensive Care Medicine</i> , 2014, 40, 202-210.	3.9	46
108	Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. <i>Critical Care</i> , 2014, 18, R58.	2.5	104

#	ARTICLE	IF	CITATIONS
109	Clinical components and associated behavioural aspects of a complex healthcare intervention: Multi-methods study of selective decontamination of the digestive tract in critical care. <i>Australian Critical Care</i> , 2013, 26, 173-179.	0.6	7
110	Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. <i>Critical Care</i> , 2013, 17, R117.	2.5	43
111	Vasopressin Guidelines in Surviving Sepsis Campaign. <i>Critical Care Medicine</i> , 2013, 41, e482-e483.	0.4	5
112	An observational study to determine the effect of delayed admission to the intensive care unit on patient outcome. <i>Critical Care</i> , 2012, 16, R173.	2.5	51
113	The Cardiopulmonary Effects of Vasopressin Compared With Norepinephrine in Septic Shock. <i>Chest</i> , 2012, 142, 593-605.	0.4	72
114	Ventricular End Diastolic Pressure (EDP). , 2012, , 2446-2446.		0
115	Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). <i>Annals of Intensive Care</i> , 2012, 2, 15.	2.2	5
116	The surgical management of injectional anthrax. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2011, 64, 276-277.	0.5	14
117	Agreement in electrocardiogram interpretation in patients with septic shock*. <i>Critical Care Medicine</i> , 2011, 39, 2080-2086.	0.4	34
118	Donation after circulatory death â€“ a new role for the anaesthetist?. <i>Anaesthesia</i> , 2011, 66, 761-764.	1.8	3
119	Vasopressin in Septic Shock. <i>Journal of the Intensive Care Society</i> , 2011, 12, 11-14.	1.1	6
120	Should Vasopressin Be Used in Septic Shock?. , 2011, , 212-217.		0
121	Sepsis: an update for physicians. <i>Clinical Medicine</i> , 2011, 11, 619-622.	0.8	0
122	Corticosteroids and the original vasopressin and septic shock trial subgroups. <i>Critical Care Medicine</i> , 2010, 38, 338-339.	0.4	1
123	The effects of vasopressin on acute kidney injury in septic shock. <i>Intensive Care Medicine</i> , 2010, 36, 83-91.	3.9	206
124	Is Selective Decontamination of the Digestive Tract a Solution to the Antimicrobial Resistance Problem in the UK?. <i>Journal of the Intensive Care Society</i> , 2009, 10, 86-88.	1.1	0
125	Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock*. <i>Critical Care Medicine</i> , 2009, 37, 811-818.	0.4	234
126	Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock. <i>New England Journal of Medicine</i> , 2008, 358, 877-887.	13.9	1,711

#	ARTICLE	IF	CITATIONS
127	Toll-like Receptor 1 Polymorphisms Affect Innate Immune Responses and Outcomes in Sepsis. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 710-720.	2.5	258
128	Low Serum Mannose-binding Lectin Level Increases the Risk of Death due to Pneumococcal Infection. Clinical Infectious Diseases, 2008, 47, 510-516.	2.9	284
129	Genes and sepsis: How tight is the fit?*. Critical Care Medicine, 2008, 36, 1652-1654.	0.4	3
130	Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Critical Care, 2006, 10, R12.	2.5	37
131	MANNOSE-BINDING LECTIN POLYMORPHISMS IN SEVERE SEPSIS: RELATIONSHIP TO LEVELS, INCIDENCE, AND OUTCOME. Shock, 2006, 25, 88-93.	1.0	86
132	Are vasopressin levels increased or decreased in septic shock?*. Critical Care Medicine, 2006, 34, 542-543.	0.4	11
133	HYPERFUNCTIONING POLYMORPHISM IN THE TOLL-LIKE RECEPTOR 1 GENE IS ASSOCIATED WITH INCREASED MORTALITY IN SEPSIS.. Critical Care Medicine, 2006, 34, A18.	0.4	0
134	Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care. Anaesthesia, 2005, 60, 340-347.	1.8	585
135	Why I do Want to be an Intensive Care Consultant. Journal of the Intensive Care Society, 2005, 6, 31-32.	1.1	0
136	Goal directed therapy: how long can we wait?. Critical Care, 2005, 9, 647.	2.5	10
137	TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes and Immunity, 2004, 5, 631-640.	2.2	96
138	How to Get Your Abstract Accepted. Journal of the Intensive Care Society, 2003, 4, 44-45.	1.1	0
139	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Protocol for the 65 randomised clinical trial. Journal of the Intensive Care Society, 0, , 175114371987008.	1.1	2
140	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension: Statistical and Health Economic Analysis Plan for the 65 trial. Journal of the Intensive Care Society, 0, , 175114371986038.	1.1	2